Form 4: Zoetis Executive Vice President Robert J. Polzer Reports Stock Option and Restricted Stock Unit Grants

Executive Vice President Robert J. Polzer reports the acquisition of stock options and restricted stock units in Zoetis Inc. on February 19, 2025.

Summary

• Robert J. Polzer, an Executive Vice President at Zoetis Inc., filed a Form 4 on February 21, 2025, reporting transactions related to Zoetis Inc. securities.
• On February 19, 2025, Polzer was granted 3,546 restricted stock units (RSUs) and 13,814 stock options under the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan.
• The RSUs vest in three equal installments on the first, second, and third anniversaries of the grant date, contingent upon continued service.
• The stock options also vest in three equal installments on the first, second, and third anniversaries of the grant date and expire ten years from the grant date.
• Polzer directly owns 3,546 RSUs granted on February 19, 2025, 1,245 RSUs granted on February 6, 2024, and 663 RSUs granted on February 8, 2023.
• Polzer also directly owns 13,814 stock options granted on February 19, 2025, 7,107 stock options, 4,840 stock options and 5,455 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it aligns management interests with shareholders.

Positives

• The grant of stock options and restricted stock units aligns Polzer's interests with those of Zoetis Inc. shareholders.
• The vesting schedule encourages continued service and commitment from the executive.

Future Outlook

The reported transactions reflect ongoing equity-based compensation practices at Zoetis Inc.

Industry Context

Equity compensation is a common practice in the pharmaceutical and animal health industries to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Zoetis' equity compensation practices are generally in line with those of its peers in the animal health industry, such as Elanco and Merck Animal Health, which also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules and terms of the grants appear to be standard for executive compensation plans in publicly traded companies.

Stakeholder Impact

• Shareholders may view the equity grants as a positive incentive for executive performance.
• Employees may see the grants as part of a competitive compensation package.

Key Dates

Keywords

Form 4, Zoetis, Stock Options, Restricted Stock Units, Executive Compensation, Polzer, ZTS